- Home
- AGIO vs HRMY Comparison
AGIO vs HRMY Comparison
Compare AGIO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- HRMY
- Stock Information
- Founded
- AGIO 2007
- HRMY 2017
- Country
- AGIO United States
- HRMY United States
- Employees
- AGIO N/A
- HRMY N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- AGIO Health Care
- HRMY Health Care
- Exchange
- AGIO Nasdaq
- HRMY Nasdaq
- Market Cap
- AGIO 2.0B
- HRMY 2.2B
- IPO Year
- AGIO 2013
- HRMY 2020
- Fundamental
- Price
- AGIO $35.22
- HRMY $34.56
- Analyst Decision
- AGIO Buy
- HRMY Strong Buy
- Analyst Count
- AGIO 7
- HRMY 8
- Target Price
- AGIO $56.33
- HRMY $54.38
- AVG Volume (30 Days)
- AGIO 621.1K
- HRMY 557.4K
- Earning Date
- AGIO 02-13-2025
- HRMY 02-25-2025
- Dividend Yield
- AGIO N/A
- HRMY N/A
- EPS Growth
- AGIO N/A
- HRMY N/A
- EPS
- AGIO 11.64
- HRMY 2.11
- Revenue
- AGIO $36,498,000.00
- HRMY $681,879,000.00
- Revenue This Year
- AGIO $166.22
- HRMY $25.11
- Revenue Next Year
- AGIO $98.36
- HRMY $19.19
- P/E Ratio
- AGIO $3.03
- HRMY $16.46
- Revenue Growth
- AGIO 36.07
- HRMY 25.83
- 52 Week Low
- AGIO $27.14
- HRMY $28.14
- 52 Week High
- AGIO $62.58
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- AGIO 54.02
- HRMY 35.54
- Support Level
- AGIO $33.25
- HRMY $37.03
- Resistance Level
- AGIO $34.86
- HRMY $39.91
- Average True Range (ATR)
- AGIO 1.33
- HRMY 1.34
- MACD
- AGIO 0.37
- HRMY -0.58
- Stochastic Oscillator
- AGIO 97.99
- HRMY 9.86
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.